Asciminib
A BCR-ABL1 inhibitor that uniquely targets the myristoyl pocket of the ABL1 enzyme rather than the ATP-binding site, overcoming many resistance mutations that limit other leukemia drugs. It is approved for chronic myeloid leukemia, including in patients with the T315I mutation.
Berat Molekul
449,8000 g/mol
LogP
3,00
TPSA
103,00 Ų
Lipinski RO5
Lulus
Area Terapeutik
Mekanisme Kerja
Inhibits the BCR-ABL fusion tyrosine kinase, the constitutively active oncoprotein responsible for driving chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits the BCR-ABL fusion tyrosine kinase, the constitutively active oncoprotein responsible for driving chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Struktur 2D
Cite this structure
Embed this structure
SMILES
O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
InChI
InChI=1S/C20H18ClF2N5O3/c21-20(22,23)31-15-3-1-13(2-4-15)26-19(30)12-9-16(17-5-7-25-27-17)18(24-10-12)28-8-6-14(29)11-28/h1-5,7,9-10,14,29H,6,8,11H2,(H,25,27)(H,26,30)/t14-/m1/s1
Molecular Formula
C20H18ClF2N5O3
HBD / HBA
3 / 8
Ikatan yang Dapat Dirotasi
6
Atom Berat
31
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Pertanyaan yang Sering Diajukan
A BCR-ABL1 inhibitor that uniquely targets the myristoyl pocket of the ABL1 enzyme rather than the ATP-binding site, overcoming many resistance mutations that limit other leukemia drugs. It is approved for chronic myeloid leukemia, including in patients with the T315I mutation.
Inhibits the BCR-ABL fusion tyrosine kinase, the constitutively active oncoprotein responsible for driving chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Yes, Asciminib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4208229. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 72165228. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="asciminib"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/asciminib/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/asciminib/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/asciminib/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="asciminib"></drugfyi-drug>